Riskpilot← Back to searchSign inGet full accessVALIDUS ENGROS AS
ASActiveOrg 914394724Orkidehøgda 3, 3050 MjøndalenWholesale of pharmaceutical and medical goods · NACE 4646Est. 20140 employees
Revenue 2022
NOK 4,7M
-19% vs 2021
EBITDA margin
-43.4%
-7% vs 2021
Equity ratio
-28.8%
Financial strength
Net profit 2022
NOK -1,6M
-8% vs 2021
| Revenue | NOK 4,7M | -19% |
| EBITDA | NOK -2M | -7% |
| Net profit | NOK -1,6M | -8% |
| Total assets | NOK 5,7M | -19% |
| Equity | NOK -1,6M | -8577% |
| Employees | 0 | — |
Legal name
VALIDUS ENGROS AS
Org number
914394724
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
3. november 2014
Share capital
NOK 5 000 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder i fellesskap.
Company purpose
Handel- og agenturvirksomhet innen helsesektoren, herunder deltakelse og eierskap i andre selskaper med lignende virksomhet, samt det som naturlig står i forbindelse med dette. Selskapet kan ha datterselskaper.
Address
Orkidehøgda 3, 3050 Mjøndalen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 234 | 661 | 1 166 | 4 260 | 12 442 | 5 778 | 4 702 |
| Staff expenses | −0 | −0 | −0 | −3 | −0 | −0 | −752 | −1 451 | −418 |
| EBITDA | −5 | −15 | −130 | 56 | 24 | 483 | 1 651 | −1 905 | −2 039 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −5 | −15 | −130 | 56 | 24 | 483 | 1 651 | −1 905 | −2 039 |
| Net financials | 0 | 0 | −0 | 1 | 4 | −22 | −115 | −50 | −70 |
| Profit before tax | −5 | −15 | −130 | 57 | 28 | 461 | 1 536 | −1 956 | −2 109 |
| Tax | −0 | −0 | −0 | −0 | −0 | 88 | 339 | −426 | −463 |
| Net profit | −5 | −15 | −130 | 57 | 28 | 372 | 1 197 | −1 529 | −1 646 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 39 | 25 | 1 617 | 1 811 | 2 070 | 2 817 | 4 782 | 6 997 | 5 656 |
| Equity | 39 | 24 | −106 | −49 | −21 | 351 | 1 548 | 19 | −1 627 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 1 | 1 723 | 1 860 | 2 091 | 2 465 | 3 234 | 6 978 | 7 282 |
| Total debt | 0 | 1 | 1 723 | 1 860 | 2 091 | 2 465 | 3 234 | 6 978 | 7 282 |
EBITDA margin
-43.4%
This company
15.8%
Market median
-375% vs market
20142022
Equity ratio
-28.8%
This company
38.2%
Market median
-175% vs market
20142022
Return on equity
-164575500.0%
This company
18.4%
Market median
-894432165% vs market
20142022
Net profit margin
-35.0%
This company
8.1%
Market median
-532% vs market
20142022
Asset turnover
0.83×
This company
1.12×
Market median
+26% vs market
20142022
Debt / equity
4.48×
This company
0.62×
Market median
-623% vs market
20142022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-09-01 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
OE Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Medivatus As | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Medivatus As
VALIDUS ENGROS AS Board members of VALIDUS ENGROS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ole Eivind Svendby | Chief Executive Officer | 0 companies |
| Pål Asbjørn Vindegg | Chairman | 0 companies |
| David Gareth Martin | Chairman | 0 companies |